Skip to content

Insider · CIK 0001478448

Thomas A MCCOURT

ceoofficerdirector

Files at IRWD (IRONWOOD PHARMACEUTICALS INC), PLRX (PLIANT THERAPEUTICS, INC.). First filing Feb 12, 2025, latest May 20, 2025.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 2
$0 bought, $252k sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

IRWD: IRONWOOD PHARMACEUTICALS INC

IRWDOct 9, 2026 · close 3.82

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
33Weak
IRWDsell 2
IRONWOOD PHARMACEUTICALS INC
$7,745
13,353 shares
-1%0% from low-89% from high
58Moderate
IRWDsell 5
IRONWOOD PHARMACEUTICALS INC
$245k
139,064 shares
-11%-

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Jun 5, 2025PLRX
PLIANT THERAPEUTICS, INC.
AGrant or award
Common Stock (Right to Buy)derivative
+30,000$0.00$030,000Jun 9, 2025
May 16, 2025IRWD
IRONWOOD PHARMACEUTICALS INC
SOpen-market sale
Class A Common Stock
-13,353$0.58$7,7451,147,281May 20, 2025
May 20, 2025IRWD
IRONWOOD PHARMACEUTICALS INC
AGrant or award
Class A Common Stock
+540,000$0.00$01,687,281May 20, 2025
Feb 10, 2025IRWD
IRONWOOD PHARMACEUTICALS INC
SOpen-market sale
Class A Common Stock
-139,064$1.76$245k1,160,634Feb 12, 2025
Jan 17, 2025IRWD
IRONWOOD PHARMACEUTICALS INC
AGrant or award
Class A Common Stock
+147,354$0.00$01,299,698Jan 22, 2025

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Thomas A MCCOURT: insider trades and track record | InsiderTell